FREMONT, Calif., Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will give a presentation on Tuesday, April 20 at this year's American Society for Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting, which is taking place from April 18-22, 2009 in New Orleans.
Dr. Thompson's presentation will be part of a session titled "Discovery and Development of Oligonucleotide Therapeutics," which is sponsored by ASPET's Divisions for Drug Discovery, Drug Development & Regulatory Affairs and Molecular Pharmacology. His talk will be on the past, present, and future of oligonucleotide therapeutics. Other leaders in RNAi will also present during the session including: Pamela A. Pavco, Vice President of Pharmaceutical Development at RXi Pharmaceuticals (topic: Special issues in the discovery and development of RNAi therapeutics); Christina Gamba-Vitalo, Senior Director Preclinical Development at Alnylam Pharmaceuticals (topic: Progress in developing siRNAs as drugs); and Patrick L. Iversen, Senior Vice President of Strategic Alliances and former Senior Vice President of Research and Development at AVI BioPharma (topic: Pharmacokinetics of oligonucleotide therapeutics).
Daniel Zurr, Ph.D., President and Chief Executive Officer of Quark, said, "We are pleased with Quark's participation in this session alongside respected leaders in RNAi development. The invitation reinforces that the drug development industry recognizes Quark's leadership position in siRNA development. Some of the Company's accomplishments include: a number of on-going clinical trials of synthetic siRNAs in various disease indications, status as the first company to administer a synthetic siRNA systemically in humans, an, enabling portfolio of IP covering synthetic siRNAs and validating partnerships with companies such as Pfizer."
Dr. Thompson has been a leader in siRNA development for several years. Prior to joining Quark, he was Director of Research and Development at Genta, and previously was Director of Biology Research at Ribozyme Pharmaceuticals, which was acquired by Merck after changing its name to Sirna Therapeutics.
No comments:
Post a Comment